SUMMARY In 25 neurological patients with detrusor hyperreflexia terodiline reduced the number of total micturitions during daytime. Bladder capacity was increased and amplitude of the bladder contractions was reduced. An increase in residual urine was also observed. Mild anticholinergic side-effects were measured on pupillary motility and on heart rate variation. It is concluded that terodil:ne is a useful alternative in treatment of patients with detrusor hyperreflexia.
Pharmacological treatment of urinary frequency and incontinence due to detrusor hyperreflexia by anticholinergic agents is often unsuccessful. Blockade of parasympathetic activity may be insufficient and, furthermore, systemic anticholinergic effects often give rise to complaints and withdrawal of therapy.' 4 Consequently, there is a need for a new pharmacological approach to the treatment of bladder hyperreflexia. Calcium blocking agents with smooth muscle relaxing properties might well be such an alternative. Recently compounds have been developed that combine an anticholinergic effect with calcium blockade. This combination could possibly improve bladder function in patients with detrusor hyperreflexia without giving rise to more systemic anticholinergic side-effects. Terodiline has shown this combined anticholinergic and calcium blocking effect in in vitro studies of muscle strip preparations' and a therapeutic clinical effect has been obtained in patients with idiopathic detrusor instability. 6 In clinical studies it has proved to be safe with only mild anticholinergic side-effects7 and systemic bioavailability of the drug is high. 8 We have conducted a randomised, placebocontrolled, double-blind, cross-over study of the effect of terodiline on bladder function in patients with detrusor hyperreflexia. Also the effect on cholinergic functions, that is, pupil motility and heart rate, as well as a possible therapeutic effect on lower limb spasticity have been evaluated.
Materials and methods
Patients with neurological diseases, urinary frequency and/or incontinence and with detrusor hyperreflexia, as defined by the International Continence Society,9 were eligible for study. Frequency was defined as eight or more passages of urine per day. Overall disability score was rated according to a previous report'0 and recorded together with body weight and blood pressure before entrance to the study and at follow-up examinations. The study was approved by the Ethical Committee and informed consent was obtained from the patients before start of the study. Exclusions Patients with urinary tract infection and patients with suspected prostatic enlargement, as evaluated from the urethral pressure profile and from the maximal urinary flow, were excluded. Patients with glaucoma, severe urinary retention, decreased liver and kidney function, and pregnant patients were also excluded. Design of study After 1 week without any medication for bladder dysfunction the patients were allocated at random to terodiline 25mg or identical placebo tablets twice daily for 4 weeks. Cross-over took place after a drug free runout period of 1 week. To avoid urinary bladder infections during the trial antibiotics were given throughout the whole investigation period. Urodynamic studies Patients were asked for preference of treatment period. To register voiding frequency and incontinence episodes they filled in a micturition chart during the last week of each treatment period. Before entrance to the study cystometry and pressure voiding were performed and at the end of the two treatment periods the cystometry was repeated, together with measurement of the residual urine.
Water cystometry was carried out with a balloon catheter transurethrally and with physiological saline as filling medium at an infusion rate of 15 Cardiovascular reflexes were studied as heart rate variation (HRV) during various conditions by simple bedside tests.12 At rest in a supine position 150 consecutive R-R intervals were recorded with no attention being paid to breathing. Heart rate variation was expressed as the standard deviation of the mean consecutive difference of R-R intervals (SDMCD), which reflects rapid shifts in beat-to-beat variation and as the standard deviation of all R-R intervals (SDR-R), a measure of longer lasting shifts in heart rate.'2 The heart rate response to deep breathing was registered for 90s at rates of 3, 4, 5, 7-5 and 10 breaths per minute, the HRV being expressed as the SD of all R-R intervals during each breathing period. The heart rate response to standing was recorded for 60 seconds and was expressed as the ratio between the 30th and the 15th heart beat. power of the lower limbs were registered in the 12 patients studied. The number of flexor spasms were counted in five patients. No changes were registered in four cases, but in one patient, elimination of detrusor hyperreflexia was followed by a 75% reduction of the number of flexor spasms.
Discussion
The present placebo controlled, clinical trial in patients with urinary bladder hyperreflexia has shown that treatment with the anticholinergic and calcium blocking agent, terodiline, reduces frequency of micturition and detrusor hyperreflexia and improves bladder capacity. The response of terodiline treatment observed in these patients with severe voiding disturbances seems similar to the response obtained in previous controlled studies of pure anticholinergic drugs.' 4 17 The clinical efficacy in the present study Petersen, Jakobsen was less pronounced compared with the efficacy in patients studied with idiopathic detrusor instability.6 However, in contrast to these studies we observed an increased residual urine in connection to depression of the detrusor hyperreflexia, as described previously. '9 20 In the present study we also observed a beneficial effect on the number of micturitions from the first to 1335 caused by bladder training as described in a previous study.2 1 The therapeutical efficacy in relation to the occurrence of side-effects (the therapeutical ratio) was high during terodiline treatment. We measured cholinergic functions of pupil motility and heart rate variation and found only mild anticholinergic effects after treatment with terodiline.2223 Side-effects were reported by nearly half of the patients, but none of them discontinued the medication. Since gain of body weight only was found in a few of our patients the suspected vasodilatory effect of terodiline is presumably small. This is supported also by the lack of reflex tachycardia. In fact we found a decrease in heart rate, most likely mediated by a calcium blockade of the sinus node. 24 Thus the degree of systemic anticholinergic sideeffects seems less pronounced compared with traditional anticholinergic therapy.' -4 17 However, urinary retention, especially in patients with detrusorsphincter dyssynergia, occurred as described after treatment with pure anticholinergic agents and management with for instance intermittent clean catheterisation should be institated when indicated.
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